Efficacy of faricimab for recalcitrant multifactorial cystoid macular edema
This case demonstrates the effectiveness of faricimab in treatment of CME resistant to other therapies and the importance of continued attempts at using new agents for chronic, recurrent CME. The unique benefits of new agents like faricimab, with both VEGF and Ang-2 inhibition, may be particularly helpful in mixed or inflammatory CME when other proven therapies have failed.
Authors
- Justin Hanson (ORCID: https://orcid.org/0000-0002-5647-7954)
- Edmund Yik Kong Tsui (ORCID: https://orcid.org/0000-0001-7532-9191)
- Irena Tsui (ORCID: https://orcid.org/0000-0001-7989-5174)
- Marcus H. Yamamoto (ORCID: https://orcid.org/0000-0001-6991-6867)
Institutions
- Doheny Eye Institute (US)
- VA Greater Los Angeles Healthcare System (US)
Publication Details
- Journal
- American Journal of Ophthalmology Case Reports
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1016/j.ajoc.2025.102475
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00